7hon MSN
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo
Eli Lilly and Co. LLY on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results